OCT 03, 2018 7:24 PM PDT

Single Cell Modified in CAR T Therapy Causes Deadly Relapse

WRITTEN BY: Carmen Leitch

One cell meant a very different outcome for a patient that was the recipient of a cutting-edge cancer therapy.  The process involves extracting a patient's immune cells, and genetically modifying them using a chimeric antigen receptor (CAR) lentivirus; it turns them into cancer killers. Those immune cells are then put back into the patients, where they go to work. However, a single cancer cell also got modified in this case. It went on to multiply billions of times, causing relapse and eventually killing the patient. The findings have been reported in Nature Medicine.

“In this case, we found that 100 percent of relapsed leukemic cells carried the CAR that we use to genetically modify T cells,” said the study’s lead author Marco Ruella, MD, an assistant professor of Hematology-Oncology at Penn Medicine. “This is the first time in hundreds of patients treated at Penn and other institutions that we’ve observed this mechanism of relapse, and it provides important evidence that steps in the delicate and complex process of engineering personalized cells can play a role in patient outcomes.”

The patient was part of a clinical trial at Penn; the aim was to treat an aggressive case of pediatric B-cell acute lymphoblastic leukemia (ALL) that had already relapsed three times. The patient's cancer went into total remission for nine months before it returned.

The therapy (described in the video) was created by scientists at Penn's Perelman School of Medicine and at Children’s Hospital of Philadelphia (CHOP). It utilizes T cells that are harvested from the patient. They are then treated with a CAR lentivirus, which trains them to find cells that express a protein called CD19. It will then attack those cells. Leukemia cells without CD19 are unaffected by this therapy.

In this case, the CAR lentivirus seems to have also gotten into a leukemia cell and enabled it to evade the immune cells. In the majority of ALL relapses, cancer cells don’t express CD19. There wasn’t any CD19 found in this patient’s cancer cells either. However, the cells tested positive for CAR. It was expressing a product that bound the CD19 antigen, so the trained immune cells could not recognize it.

Interestingly, the opposite case happened earlier this year. A single CAR T cell was able to divide enough times that it destroyed chronic lymphocytic leukemia (CLL).

“We learn so much from each patient, in both success or failure of this new therapy, that helps us improve these still-developing treatments so they can benefit more patients,” noted the senior author of this work, J. Joseph Melenhorst, PhD, an associate professor of Pathology and Laboratory Medicine and a member of Penn’s Center for Cellular Immunotherapies.

“This is a single case, but is still incredibly important and can help us refine the intricate processes required for manufacturing CAR-T cell therapy to ensure the best chance of long-term remissions,” he added.


Sources: Penn Medicine, Nature Medicine

About the Author
BS
Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
APR 19, 2022
Genetics & Genomics
In Early Embryonic Development, Gene Expression Goes Wild
APR 19, 2022
In Early Embryonic Development, Gene Expression Goes Wild
Genes are transcribed from DNA into RNA, which is then processed in various ways before being translated into proteins. ...
APR 20, 2022
Health & Medicine
The Link between Mental Health and COVID Breakthrough Infection
APR 20, 2022
The Link between Mental Health and COVID Breakthrough Infection
Researchers from University of California San Francisco and the San Francisco Veterans Affairs Health Care System conduc ...
APR 20, 2022
Immunology
Rare Soil Microbe Shows Promise as New Antibiotic
APR 20, 2022
Rare Soil Microbe Shows Promise as New Antibiotic
  Antibiotic resistance has increased the demand for new antibiotic treatments. Now, researchers have found that a ...
APR 28, 2022
Cancer
Can Urine Help Detect Prostate Cancer?
APR 28, 2022
Can Urine Help Detect Prostate Cancer?
It is estimated that over 250.000 men in the United States will receive prostate cancer diagnoses in 2022, acc ...
MAY 21, 2022
Cell & Molecular Biology
The Effect of a Genetic Mutation Can Change Over Time, and Evolution
MAY 21, 2022
The Effect of a Genetic Mutation Can Change Over Time, and Evolution
Geneticists have sought to understand the impact of genetic mutations, and what drives and maintains changes in DNA.
MAY 23, 2022
Neuroscience
Cerebrospinal Fluid From Young Mice Improved Memory in Old Mice
MAY 23, 2022
Cerebrospinal Fluid From Young Mice Improved Memory in Old Mice
As many as one quarter of all adults over the age of 60 experience age-related cognitive decline. This cognitive decline ...
Loading Comments...